NR2C2AP抗体 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07672(NR2C2AP Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The NR2C2AP (Nuclear Receptor Subfamily 2 Group C Member 2 Antisense Protein) antibody is designed to target a protein encoded by an antisense transcript of the NR2C2 gene. NR2C2. also known as TR4 (testicular receptor 4), belongs to the nuclear receptor superfamily and regulates gene expression by binding to hormone response elements. The antisense transcript NR2C2AP, located on chromosome 12q15. is a long non-coding RNA (lncRNA) implicated in modulating NR2C2 activity through epigenetic or post-transcriptional mechanisms.

Research suggests NR2C2AP plays a role in cellular processes like proliferation, differentiation, and apoptosis. Dysregulation of NR2C2AP has been linked to cancers, including prostate and breast cancer, where it may act as an oncogene or tumor suppressor depending on context. Its interaction with signaling pathways such as Wnt/β-catenin and PI3K/AKT highlights its potential involvement in tumorigenesis.

The NR2C2AP antibody is a critical tool for detecting endogenous NR2C2AP expression and localization in tissues or cell lines via techniques like Western blot, immunohistochemistry, or immunofluorescence. It aids in elucidating the protein’s molecular functions, particularly its interplay with NR2C2 and other regulatory networks. Studies using this antibody contribute to understanding disease mechanisms, biomarker discovery, and therapeutic targeting. However, challenges remain in fully characterizing its biological roles due to the complexity of lncRNA-protein interactions. Validating antibody specificity through knockdown/knockout controls is essential to ensure reliable experimental outcomes.